Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 88-93

  Angioli, R ^a   Palaia, I ^b   Calcagno, M ^b   Manci, N ^b   Zullo, M A ^a   Bellati, F ^b   Perniola, G ^b   De Vivo, A ^a   Benedetti Panici, P ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Gynecological neoplasms; Liposome encapsulated doxorubicin citrate; Palliative chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; LIPOSOME; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENCAPSULATION; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FEMALE; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CITRATES; DOXORUBICIN; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE;

EID: 33846827295     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00825.x     Document Type: Article

References (28)

1. Zambon P, La Rosa F. Gynecological cancers: cervix, corpus uteri, ovary. Epidemiol Prev 2004;28:68-74.
2. Vermorken JB, Kobierska A, van der Burg ME et al. High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. Eur J Gynaecol Oncol 1995;16:433-8.
3. Vermorken JB, ten Bokkel Huinink WW, Kobierska A et al. Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma. Oncology 1999;57:10-6.
4. Pelaez I, Lacave AJ, Palacio I et al. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer 1996;32A:899-900.
5. Havsteen H, Bertelsen K, Gadeberg C et al. A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer. Gynecol Oncol 1996;63:210-5.
6. Wong LC, Choy DT, Ngan HY, Sham JS, Ma HK. 4-epidoxorubicin in recurrent cervical cancer. Cancer 1989;63:1279-82.
7. Calero F, Jimeno J, Rodriguez-Escudero F et al. Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer. Eur J Gynaecol Oncol 1992;13:83-9.
8. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979;63:21-7.
9. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408-14.
10. Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978;62:159-61.
11. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;12:660-8.
12. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumours. Proc Natl Acad Sci USA 1988;85:6949-53.
13. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 1997;280:1319-27.
14. Gordon KB, Tajuddin A, Guitart J et al. Hand-foot sindrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-73.
15. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997;15:3185-91.
16. Alexopoulos A, Karamouzis MV, Stavrinides H et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004;15:891-5.
17. Valero V, Buzdar AU, Theriault RL et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999;17:1425-34.
18. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
19. Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36.
20. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001;19:1444-54.
21. Chan S, Davidson N, Juozaityte E et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004;15:1527-34.
22. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
23. Israel VP, Garcia AA, Roman L et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000;78:143-7.
24. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
25. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20:2360-4.
26. Therasse P, Arbuck SG, Eisenheuer EA et al. New guidelines to evaluate the response to treatment in solid tumor. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
27. Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
28. Alberts DS, Muggia FM, Carmichael J et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004;31(Suppl. 13):53-90.